Objective: Oral supplements of fenugreek (Trigonella foenum graecum) seeds (Fen) have been shown to treat glucose and lipid homeostasis in several metabolic disorders; however, its ability to alleviate obesity-associated pathologies is not known. The main objective of this study was to evaluate the effect of Fen in Zucker obese rats (Ob), an animal model of obesity and related disorders, such as dyslipidemia and hepatic steatosis. Methods: Female Zucker (6-week-old) Ob and lean (Ln) rats were randomly grouped (n ¼ 8 rats/group) to receive either basal or 5% Fen-supplemented AIN-93G diets for 8 weeks, and then were euthanized. Histopathology and biochemical parameters in the liver together with plasma biochemistry were assessed. Results: Obese rats had significantly higher (Po0.05) body and liver weight, as well as plasma insulin, lactate, cholesterol, triglyceride and tumor necrosis factor (TNF)-a compared to their Ln counterparts. Fen significantly reduced (Po0.05) the liverweight of Ob rats in comparison to Ob rats fed basal diet (Control), while no effect was observed in the Ln rats. Fen treatment resulted in a lower P-value (Po0.05). In addition, Ob rats on Fen-supplemented diets had fasting plama cholesterol and TNF-a levels, and significantly higher (Po0.05) triglycerides in comparison to the control rats. Hepatic triglyceride level was significantly lower (Po0.05) in Ob rats fed Fen supplemented diets in comparison to control. The levels of bound and soluble liver TNF-a (26 and 17 kDa, respectively) and TNF receptor-II (TNFR-II, 75 kDa) proteins were significantly lower (Po0.05) in Ob than in Ln rats. Fen significantly lowered (Po0.05) both the soluble and bound forms of TNF-a protein while significantly elevating (Po0.05) TNFR-II in the livers of Ob rats compared to Ob Controls. Conclusion: These results demonstrate unequivocally that in a short-term preclinical evaluation, dietary Fen supplementation reduced the triglyceride accumulation in the liver, a hallmark feature of hepatic steatosis without affecting the plasma insulin or glucose levels in Zucker obese rats and suggest that TNF-a may play an important role in this process.
Introduction
The etiology and pathogenesis of obesity and its associated disorders are multifactorial and involve a complex interaction of predisposing genetic factors and lifestyle factors including but not limited to high-energy intake and physical inactivity. 1 There is a strong link between the obese state and the risk of developing several diseases, such as cardiovascular and liver disorders, dyslipidemia, insulin resistance, type-2 diabetes, hypertension, metabolic syndrome X and certain types of cancers. 2 The Zucker obese (Ob) rat is an ideal experimental model to test and refine hypotheses linking genetic and environmental factors in the etiology of metabolic diseases, such as diabetes, hypertension, dyslipidemia, heart disease and liver disease. [3] [4] [5] Ob rats inherit obesity as an autosomal Mendelian recessive trait (fa/fa, homozygous for nonfunctional leptin receptors), and exhibit hyperphagia, hypertriglyceridemia, hypercholesterolemia, hyperinsulinemia and mild hyperglycemia. 6, 7 It is also purported that tumor necrosis factor (TNF)-a, an important cytokine is elevated in the plasma as well as several tissue types in Ob rats. 8, 9 Excessive circulating TNF-a potentiates disarray in a number of metabolic pathways leading to obesity-associated complications. 10, 11 Modalities to prevent and control obesity and its associated disorders include a combination of nutrition and diet, physical activity and change in behavioral regimens. 1 Several dietary components including those that are derived from plant/herbal sources may play an important role in the prevention and treatment of obesity and its associated complications as many of these have purported to elicit lipid-lowering functions. Dietary supplementation of the seeds of Trigonella foenum greacum (Fabaceae), commonly called fenugreek, was shown to lower serum cholesterol, triglyceride and low-density lipoprotein in animal models of hypercholesterolemia. [12] [13] [14] Findings of several human intervention trials have demonstrated that dietary fenugreek seeds (Fen) lowered serum cholesterol and triglyceride levels. [15] [16] [17] [18] Moreover, oral supplements of Fen were shown to ameliorate most metabolic symptoms associated with type-1 and type-2 diabetes in both humans and relevant animal models. 19 Fen is currently available commercially in encapsulated forms and is being prescribed as dietary supplements for the control of hypercholesterolemia and diabetes by practitioners of complementary and alternative medicine. 20 The known health beneficial effects of Fen owes to its chemical composition that include but not limited to mucilaginous fiber, lysine-rich protein, free amino acids, saponins, flavonoids, and volatile oils. Fen is rich in saponins such as diosgenin [(25R)-spirost-5-en-3b-ol], and B0.28-0.92% was reported to be recovered from high-yielding seeds. 21 Diosgenin has been shown to elicit hypocholesterolemic and anticarcinogenic activity. [22] [23] [24] One of the active components of Fen, free amino acid 4-hydroxyisoleucine (4-OH-Ile) has been purported to act as an insulinotropic agent. 25 The main objective of this study was to assess the health beneficial efficacy of Fen in Ob rats. The most important finding of this study is that oral administration of 5% Fen for 8 weeks significantly reduced hepatic steatosis commonly observed in Ob rats by reducing hepatic weight and triglyceride level with a concomitant reduction in plasma TNF-a but not insulin or glucose level. Fen affected the expression of TNF-a and the type-II TNF receptor (TNFR-II) in the hepatic tissue of Ob but not in lean rats.
Materials and methods
Animals, care and diets Five-week-old female Ob (fa/fa) rats (n ¼ 16) and their lean (Fa/Fa) counterparts (n ¼ 16) were procured from Charles River Laboratories (Wilmington, MA, USA) and housed in suspended wire cages approximately 10 cm above sawdust bedding trays with a 12-h light/12-h dark cycle, in the animal housing facility. Temperature and relative humidity were controlled at 221C and 55%, respectively. All animals were acclimatized to the above conditions for 1 week with free access to standard laboratory rodent chow and drinking water until initiation of the experiment. All animals were cared for according to the guidelines of the Canadian Council on Animal Care. The control and Fen-supplemented experimental diets were based on a semisynthetic AIN-93G standard diet formula containing 5% corn oil by weight. 26 Fen was a gift from Dr Peter R Chang (Agriculture and AgroFood Canada Research Center, Saskatoon, SK, Canada). Fen was powdered in a blender and passed through a fine sieve; the resultant powder was stored at 41C in amber glass containers. The control diet contained no Fen, while the Fen-supplemented diet contained 5% powdered Fen (w/w) and was substituted for corn starch. The dose was selected based on the observation that 5% Fen exerted health beneficial effects in animal models of type-1 and type-2 diabetes, [27] [28] [29] and its nontoxicity to rats as previously reported. 30 Diets were prepared twice each week and were stored in dark at 41C until used. Food cups were replenished every alternate day with fresh diets and rats were allowed ad libitum access to the experimental diets and drinking water.
Experimental design and euthanasia At 6-weeks of age, a week after acclimatizing in the laboratory conditions, Ob and lean rats were randomly assigned to either control or Fen-supplemented diets (n ¼ 8 rats/group). Body weights and food intake were monitored routinely on a daily basis. The rats remained on the respective diets for 8-weeks, after which, they were fasted for 12 h overnight, weighed, and euthanized by CO 2 asphyxiation. Following euthanasia, gross anatomy was observed, and blood was drawn into a vacutainer (Becton Dickinson Vacutainer Systems, Franklin Lakes, NJ, USA) from a heart puncture using a multiple sample Luer adapter.
Fractions of blood were processed for determining plasma insulin, glucose, cholesterol, triglyceride and lactate levels. The entire liver was dissected out; weights were noted and the lobes were separated. The left and the right medium lobes were used for lipid extraction; the right lateral lobe was used for histology, whereas the remaining liver was processed for other biochemical investigations. Samples were snap frozen in liquid N 2 and stored at À801C. For histological observation, segments of the liver were fixed in buffered formalin for a period of 48 h and processed for serial sectioning. Transverse sections (4 mm) were made and stained with hematoxylin and eosin. The livers were graded for the degree of steatosis as described previously by Li et al. Western blot analyses of tumor necrosis factor-a and tumor necrosis factor receptor type-II Liver tissues frozen at À801C were homogenized in 50 mM Tris-HCl (pH 7.4) with 1.0% NP-40 and protease inhibitors, and total proteins were quantified using a Coomassie protein assay reagent (Pierce Biotechnology Inc., Rockford, IL, USA). To avoid overloading of the gel and to determine the level of a specific protein in the homogenates, increasing total protein concentrations of the samples were run to establish a linear range, and the amount selected fell within that range. A positive control was included in all of the gels to minimize background and gel-to-gel variability. Equal loading of samples were checked by performing immunoblotting with b-actin house-keeping protein. Volumes of liver homogenates containing equal microgram of proteins were heated for 4 min at 801C with 2 Â 2% (w/v) SDS sample buffer containing 5% (v/v) b-mercaptoethanol, 10% (w/v) glycerin, 0.001% (w/v) bromphenol blue, and 63 mM Tris-HCl (pH 6.8) and separated by 10% SDS-PAGE using the Mini-Protean Bio-Rad-III system (Bio-Rad Laboratories Ltd., Hercules, CA, USA). The separated proteins were transferred to PVDF membranes (Bio-Rad Laboratories Ltd., Hercules, CA, USA).
Membranes were blocked for 1 h at room temperature with 5% skim milk powder and then probed with primary antibodies. Mouse anti-TNF-a and anti-b-actin antibodies (Cat. # T3198 and A5441, respectively; Sigma-Aldrich Ltd., St Louis, MO, USA) at dilutions of 1:1000, and rabbit anti-TNFR-II antibody (Cat. # sc-7862, Santa Cruz Biotechnologies, Santa Cruz, CA, USA) at a dilution of 1:100 were used. Blots were washed and incubated with secondary anti-mouse antibody (for TNF-a and b-actin) or anti-rabbit antibody (for TNFR-II) conjugated with horseradish peroxidase (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) for 1 h at room temperature. After washing, the blots were incubated with SuperSignal s West Pico Chemiluminescent Substrate (Pierce Chemical Co., Rockford, IL, USA) for 5 min and exposed in a FluorChem Imaging Systems (Alpha Innotech Corp., San Leandro, CA, USA). Densitometric analysis was conducted on visible protein bands using the FluorChem Imaging Systems (Alpha Innotech Corp., San Leandro, CA, USA).
Statistical analysis
Statistical analysis of the data was performed using the SigmaStat 2.0 for Windows software (SPSS Inc., Chicago, IL, USA). Differences between groups were determined by ANOVA followed by Student's t-test and values with Po0.05 were regarded as significant.
Results
Fenugreek exerted no adverse effects in Zucker obese and lean rats Oral administration Fen at a dose of 5% had no effect on body weight gain, eating habits or any behavioural changes in any of the Ob or lean rats routinely observed ( Table 1) . Irrespective of Fen treatment, body weights were significantly higher in the obese than in lean rats (Table 1) , and this difference existed throughout the study. No difference was observed in food intake, calculated as mean weight of food (g) per animal per day, between Fen-treated and untreated obese or lean rats (Table 1) . 
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Fenugreek reduced the liver weight and alleviated hepatic steatosis in obese rats Except for the liver and kidney, there were no notable differences in the organ weights of either obese or lean rats compared to that in their Fen-treated counterparts ( Table 1) . The wet liver weight and the liver weight per 100 g body weight were significantly lower (Po0.05) in the Fen-treated obese rats compared to those which were fed the basal diet (Table 1) . However, there were no significant changes in weights or appearance of the livers between the Control and Fen treated lean rats (Table 1) . A significant decrease in kidney weight was also observed in Fen-treated obese rats compared to that of Control obese rats, and no effect of Fen was observed in the lean rats ( Table 1 ). All animals were randomly coded and therefore during the necropsy gross appearances of the organs were assessed blindly. Liver in control untreated obese rats grossly appeared to be pale with cream colored marbling pattern; this effect was not as pronounced in any of the obese rats fed the Fen-supplemented diet. In fact, the gross appearance of the livers of the latter was comparable to that of the lean rats. Histologically, hepatic steatosis was observed only in obese rats and not in their lean counterparts ( Figure 1 ). In obese rat livers, 470% of the hepatic parenchyma was observed to be occupied by fatty hepatocytes accounting to Grade 3 type of steatosis ( Figure 1 ). Fen remarkably reduced the degree of hepatic steatosis in obese rats and a large portion of the hepatic tissue in this group appeared similar to the lean rats ( Figure 1 ). Fen had no effects on the liver histology of lean rats (results not shown). In Fen-treated obese rats, o5% of the hepatocytes had visible lipid accumulation compared to marked accumulation (470%) noted in the livers of obese rats fed the basal diet (Figure 1 ).
Fenugreek caused an increase in plasma triglycerides and a decrease in cholesterol without affecting glucose or insulin in obese rats Rats were fasted for 12 h prior to collection of blood. Plasma glucose (Figure 2a Fenugreek lowered plasma tumor necrosis factor-a level in obese rats Irrespective of the dietary treatment, obese rats (Ob and ObFen) had significantly higher levels (Po0.05) of TNF-a compared to the lean counterparts (Zucker lean (Ln) and Ln-Fen). Fen-treatment significantly reduced (Po0.05) plasma TNF-a level in obese rats compared to that noted in the obese Controls (Ob) (Figure 2f ). No differences in plasma Modulation of plasma and liver TNF-a levels in Zucker obese rats J Raju and RP Bird TNF-a level were observed between the Fen-treated or untreated lean rats.
Fenugreek decreases total fat and triglycerides in the livers of obese rats The differences between obese and lean rats with regards to the total fat content as well as triglycerides and phospholipids in the liver were significant (Po0.05) ( Table 2 ). The level of total fat was significantly lower (Po0.05) in Fen-treated obese rats than in the obese Control. The liver triglyceride was significantly lower (Po0.05) in Fen-treated rats by comparison to untreated obese rats; the values expressed as % triglyceride was significantly lower (Po0.05) when expressed either as per gram liver weight or in relation to the total fat (Table 2 ). No visible difference in levels of phospholipids when expressed as milligram per gram liver weight. These parameters were unaffected by Fen in the liver of lean rats (Table 2) .
Fenugreek increased hepatic 18:2 o-6 fatty acid in obese rats Fatty acid composition of liver triglyceride and phospholipid fractions from Ob and lean rats are presented in Tables 3  and 4 . In the liver triglyceride fractions, a significantly higher (Po0.05) percentage of saturated, except for C18:0, and o-9 fatty acids accompanied with a significantly lower percentage (Po0.05) of 18:2 o-6 and 20:4 o-6 was noted in the obese rats fed a basal diet compared to their lean counterparts (Table 3) . Fenugreek supplementation caused a significant decrease (Po0.05) in the percent level of 18:1 o-9 and a significant increase (Po0.05) in 18:2 o-6 and 20:4 o-6 levels in the obese rats, and had no effect in the lean rats (Table 3 Modulation of plasma and liver TNF-a levels in Zucker obese rats J Raju and RP Bird significantly decreased (Po0.05) the percent of 18:1 o-9 and increased (Po0.05) the percent of 18:2 o-6 fatty acids only in obese rats (Table 4) .
Fenugreek lowered tumor necrosis factor-a and elevated its receptor in obese rat liver Our results demonstrate that there were no differences in the expression of b-actin, the housekeeping protein in any of the samples, this confirmed equal loading and served as a control to compare between groups and across gels (Figure 3) . Two major bands at 26 and 17 kDa were detected in the liver homogenates of Ob and lean rats representing the bound and soluble forms of TNF-a, respectively (Figure 3 ). Irrespective of Fen treatment, the protein levels of both 26 and 17 kDa forms of TNF-a were significantly lower (Po0.05) in the livers of obese than in lean rats (Figure 4 ). 
Discussion
Plants and their constituents, especially those that are incorporated as condiments and foods, have been widely used in alternative and complementary medicine to prevent and treat obesity and associated complications. 33 The scientific merit and efficacy of several plant constituents in the prevention and treatment of liver disease and their mechanisms of action has been described previously. Modulation of plasma and liver TNF-a levels in Zucker obese rats J Raju and RP Bird
34,35
Seeds of fenugreek are currently used as an alternative and complementary medicine in the prevention of hypercholesterolemia and diabetes. 19, 20 To our knowledge, this is the first study to examine the effect of Fen in an animal model of obesity and associated disorders. The most important findings of this study are: (1) Fen reduced the liver weights, alleviated hepatic steatosis and decreased the levels of hepatic triglyceride in Ob rats; (2) Fen decreased plasma cholesterol exclusively in obese but not in lean rats; (3) Fen reduced the levels of plasma TNF-a and modulated the expression of TNF-a and its receptor in the livers of obese rats.
In the present study, we demonstrate that supplementation of Fen in the diet at a dose of 5% (w/w) was tolerable by both obese and lean rats through out the experiment and no adverse health effects were observed. This finding is congruent to a previous report by Muralidhara et al. 30 who demonstrated that doses of Fen between 1 and 10% of diet (w/w) did not produce any acute or cumulative toxicity in both mice and rats. In a recent study, extracts of Fen were found to be nongenotoxic when evaluated using the reverse mutation assay, mouse lymphoma forward mutation assay and mouse micronucleus assay as recommended by the United States Food and Drug Administration for food ingredients. 36 In human studies, a dosage of 100 g per day has been used with health beneficial effects. 19 The 5% dose used in this study would relate to a daily dose of B1.2-1.5 g for Ob and lean rats based on their average daily food intake. The effect of Fen in lowering the liver weight was conspicuous, exclusively in Ob rats; and histological analyses confirmed that Fen reduced hepatic steatosis. This effect of Fen was accompanied by lower level of total fat in the liver by comparison to the nontreated obese rats. Aberration in lipid homeostasis in the liver is characteristic of obesityassociated hepatic steatosis; 37, 38 and a key strategy in its control is to normalize hepatic histopathology and abnormal lipid metabolism. 39 While we anticipated that Fen would have lowered liver triglycerides by either improving lipid oxidation or decrease lipogenesis in the liver, our finding that Fen-supplementation caused an increase in plasma triglycerides in obese rats compared to their un-treated controls was unexpected, and seems to underplay this theory. In a similar experimental strategy, dietary oligofructose lowered liver weight in Ob rats without reducing hypertriglyceridemia. 40 We propose that Fen was able to reduce the hepatic triglyceride level by enhancing triglyceride release into the blood system, hence owing to higher levels in the plasma. The elevated plasma triglyceride is normally considered to be detrimental to health leading to the risk of cardiovascular complications. However, since increased triglyceride was noted with a concomitant reduction in hepatic steatosis, it could be speculated that over a long-term treatment regimen, a reduction in triglyceride levels may be achieved and this should be considered in future studies.
In the present study, the plasma triglycerides levels were assessed in the fasted state and this reflected the endogenous sources of lipids. The hepatic triglycerides demonstrated higher percentage of saturated and unsaturated, and o-9 fatty acids in obese rats compared to that in the lean state, suggesting that endogenous synthesis of fatty acids could have been elevated in obese rats resulting in a lower percent of essential fatty acids such as 18:2 and 20:4 o-6. The ability of Fen to increase the percentage of unsaturated fatty acids in the liver may be related to reduced fatty acid and triglyceride synthesis. It is reasonable to suggest that dietary Fen reduces steatosis or accumulation of triglycerides in the liver, in part by modulating the de novo synthesis of triglycerides and by channeling the triglycerides out of the liver. Generally, lower levels of long-chain fatty acids such as C22:5 o-6 and C22:6 o-3 were noted in obese rats in both phospholipid and triglycerides by comparison to their lean counterparts. This finding is intriguing considering that diets fed to all groups had the same fatty acid composition (from 5% corn oil, w/w), and potentially reflects a lower fatty acid de-saturation and elongation in obese rats by comparison to their lean counterparts. No consistent effect of Fen-feeding was noted on these parameters. Fenugreek has been shown to modulate the activities of key enzymes involved in hepatic lipogenesis in experimental type-1 diabetes, that is, in the absence of insulin. [27] [28] [29] Ob rats display hyperinsulinemia and the effect of Fen to modulate the activities of enzymes involved Modulation of plasma and liver TNF-a levels in Zucker obese rats J Raju and RP Bird in hepatic lipogenesis, previously shown in experimental type-1 diabetes, 27 cannot be entirely ruled out and requires further investigation. Aqueous extracts of Fen significantly reduced ethanol toxicity in rats by modulating activities of enzymes involved in hepatic lipid peroxidation. 41 Although the etiology of alcoholic and nonalcoholic hepatic steatosis may differ, 42 it is plausible that Fen may control hepatic steatosis in part by reducing lipid peroxidation in the Ob rats. Fenugreek has been shown to improve glucose homeostasis in experimental type-1 diabetes in a hypoinsulinemic state. 27 It is important to note that in the present study Fen did not reduce plasma glucose or insulin levels in Ob rats. This finding suggests that the effect of Fen or its constituents as insulinotropic agents in modulating glucose homeostasis is possibly more pronounced in type-1 diabetes characterized by the lack of insulin, than in an obese state associated with hyperinsulinemia. Hyperglycemia encountered in the Ob rats is the resultant of the insulin-resistant state occurring in the presence of excessive plasma insulin levels. In a recent study, it was reported that a diet rich in Fen (B7% w/w) significantly increased the expression of apo B,E receptor and the activity of triglyceride lipase in artherogenic rat liver by comparison to the Control, thereby improving cholesterol homeostasis. 43 There have been several reports of the hypocholesterolemic effects of Fen, by lowering both hepatic and systemic cholesterol levels. 14, [27] [28] [29] In the present study, we observed the ability of Fen to decrease systemic levels of cholesterol only in obese rats. By combining the results of our study and those of others, it is proposed that Fen has a potential to improve cholesterol metabolism in Ob rat, thus contributing to improvement of lipid homeostasis in the liver. It is well understood that TNF-a, an important cytokine is abundant in the blood and various tissues of obese and/or insulin-resistant subjects. 8, 9 Zucker obese rats have elevated plasma TNF-a compared to their lean counterparts. 10 TNF-a is purported to act as an important instigator in the pathogenesis of obesity and associated pathologies. 10, 11 In relation to its effect in hepatic steatosis, TNF-a stimulates hepatic lipogenesis and increases the release of free fatty acids from adipocytes, resulting in an accumulation of liver triglycerides. 11 Moreover, the continuous presence of TNF-a in association with other proinflammatory cytokines induce secondary changes required for inflammation, cell death and fibrosis in the liver, hence facilitating the disease progression, as proposed in the 'two-hit' model by Day et al. 44, 45 It appears that both exogenous TNF-a from proinflammatory and other extra-hepatic cells, as well as those endogenously produced by the hepatocytes, may conjure complex molecular disarrays in other signaling pathways, including those mediated via nuclear factor (NF)-kB, insulin receptor and peroxisome proliferator-activated receptor during hepatic steatosis. 10, [46] [47] [48] Mechanistically, TNF-a exerts several biological functions via its receptor belonging to the TNF receptor (TNFR) superfamily. 49 TNF/TNFR signaling plays a key role in normal biological functions such as organogenesis, maintenance of the lymphatic system, and host immune responses; it also plays a crucial role in the pathogenesis of several metabolic diseases as described earlier. 49 TNFR-I and -II are two main receptors for TNF-a among the nearly 40 members of the TNF/TNFR superfamily. While TNFR-I is involved in FAS/TRAIL/DR mediated signaling primarily in apoptosis, TNFR-II is involved in TNF-receptor associated factor (TRAF) mediated NF-kB and phosphoinositide 3-kinase (PI3K) signaling for cellular events including proliferation, growth and survival. The two receptors (TNFR-I and -II) coexist as bound forms on the surface of several cell types and their release as soluble forms has also been noted. TNF-a exists as bound (26 kDa) or soluble (17 kDa) forms, and depends on its ability to bind to TNFR-I or -II. Our finding that Ob rats have higher levels of plasma TNF-a (soluble form) than their lean counterparts is congruent with earlier studies. 10 However, this was not the case in the liver TNF-a expression pattern; obese rats had lower levels of both bound and soluble hepatic TNF-a compared to that in the lean rats. We propose that increased plasma level of TNF-a is in part, due to its rapid release from other tissues to the vascular bed including that released from the fatty liver. Dietary Fen supplementation lowered TNF-a in the plasma as well as in the livers of Ob rats suggesting that Fen may have decreased TNF-a synthesis or its turnover rate. In the current study, repeated analyses of the tissues demonstrated that hepatic TNFR-II expression was consistently lower in the control obese than in the lean state. The phenomenon of TNFR shedding has been described earlier and is purported to be augmented by several factors including elevated levels of metalloproteases and cytokines including TNF-a in the blood stream. 50, 51 The soluble TNFR in the vascular bed binds with soluble TNF-a leading to the formation of 'slow release reservoirs' to biological stabilization of the latter. 52 There are several explanations to our effects of augmented expression of TNFR-II observed in the livers of Fen-treated obese rats.
Decreased plasma TNF-a may reduce the shedding of membrane bound hepatic TNFR-II, by a feed-back regulation. Reduced TNFR-II shedding in the liver could also decrease the level of soluble TNF-a in the vascular bed and increase the turnover rate. These explanations need to be validated by assessing the plasma level of soluble TNFR-II and TNF-a complex. The ability of Fen to reduce hepatic steatosis and expressions of hepatic TNF-a and TNFR-II in Ob rats was unexpected. It is also noteworthy that the effect of Fen in Ob rats is quite different from that observed in their lean counterparts.
In conclusion, Fen significantly alleviated hepatic steatosis in Ob rats, which was demonstrated histologically and biochemically. This hepatotropic beneficial effect of Fen was accompanied by reduced plasma TNF-a and altered expression of hepatic TNF-a and TNFR-II exclusively in obese rats. These findings are novel and provide a strong impetus to explore the therapeutic benefit of Fen and its active components in hepatic steatosis associated with obesity and insulin resistance, and the potential role of TNF-a-mediated signaling pathway in this process.
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